NYU Langone and NYU Grossman in the News
NYU Langone throws Halloween party for pediatric cancer patients
New York Post
The NYU Langone Cancer Center for Kids—Mineola hosted its annual Halloween party for pediatric patients and their families, providing a festive environment with costumes, candy, and pizza. The event offers children and their families an experience of joy and normalcy during challenging times. Kim Krupa, a certified child life specialist at the center, explained that the party provides a guaranteed safe celebration for families. The article highlights the positive impact on several young patients, noting that the event creates a strong sense of community for families going through similar experiences.
Also reporting was: Head Topics
10/14/2026
Doctor encourages New Yorkers to get flu and COVID shots
Spectrum News NY1
As flu season begins, health experts are encouraging New Yorkers to get vaccinated. Isaac P. Dapkins, MD, chief medical officer of the Family Health Centers at NYU Langone, joined NY1 anchor Shannan Ferry on News All Day to discuss this year’s flu and COVID shots.
10/14/2026
Depression in OB-GYN residents needs more attention, study suggests
Medical Xpress
A study in the American Journal of Obstetrics and Gynecology finds that one-third of OB-GYN residents may develop clinical depression during their first year of training. The research, part of the national HERO Project, also found that only one-third of residents who developed depression sought mental health care. The project's co-principal investigator is Abigail Winkel, MD, MHPE, professor and vice chair of education in the Department of Obstetrics and Gynecology at NYU Grossman School of Medicine. The authors suggest that residency programs should consider automatically providing support to all residents.
Also reporting was: Newswise, SCIENMAG, News Medical
10/14/2026
Weighing real-world data on infection risk in CLL
OncLive
This article weighs the value of real-world data against clinical trial data for assessing infection risk in chronic lymphocytic leukemia (CLL). Marc J. Braunstein, MD, PhD, associate professor of medicine at NYU Grossman Long Island School of Medicine, supports real-world studies, noting they reflect how most patients are treated outside of a trial's strict oversight. He argues that these larger cohorts, which include patients often excluded from trials, more accurately represent infection rates and efficacy outcomes once drugs are approved and are especially useful for tracking adverse events.
10/14/2026
Key takeaways on infection risk in CLL treatment selection
OncLive
In a discussion, Marc J. Braunstein, MD, PhD, associate professor of medicine at NYU Grossman Long Island School of Medicine, discusses weighing infection risk in chronic lymphocytic leukemia (CLL) treatments. He identifies the primary decision as being between continuous versus fixed-duration therapy. Dr. Braunstein emphasizes counseling patients that even chemotherapy-free options carry a significant risk of infection, a major cause of morbidity and mortality. He also stressed the importance of following guideline recommendations on vaccination and infection prevention to mitigate these risks.
10/14/2026
Next-generation KRAS inhibitors and practice change
OncLive
In a discussion on next-generation KRAS inhibitors for non-small cell lung cancer, Rajwanth Veluswamy, MD, clinical associate professor of medicine at NYU Grossman School of Medicine, expressed excitement about several new drugs. Citing recent data, he highlighted daraxonrasib, divarasib's ongoing phase 3 trial, and zoldonrasib, a molecular glue showing a benefit signal in most patients. Dr. Veluswamy added that retiring docetaxel from second-line treatment would require a new agent to show substantial progression-free and overall survival benefits.
10/14/2026
Key takeaways on KRAS G12C management
OncLive
Rajwanth Veluswamy, MD, clinical associate professor of medicine at NYU Grossman School of Medicine, and Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, shared key takeaways on managing KRAS G12C-mutated non-small cell lung cancer. Dr. Veluswamy advised testing every patient for KRAS and co-mutations, noted that immunotherapy offers durable benefits, and highlighted that the field is exploring combination strategies to improve outcomes. Dr. Jani added that he is closely watching pan-RAS inhibitors as they enter clinical trials, expressing optimism about their potential.
10/14/2026
Closing remarks and emerging data outlook
OncLive
In a discussion with Rajwanth Veluswamy, MD, clinical associate professor of medicine at NYU Grossman School of Medicine, Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, shared his outlook on emerging data for KRAS-mutated non-small cell lung cancer (NSCLC). Dr. Jani is closely watching clinical trials of new KRAS G12C- and G12D-specific inhibitors and combination approaches. He expressed hope that emerging data could soon transition KRAS G12C from a non-actionable to a fully actionable alteration in stage IV NSCLC, a significant development for other KRAS-mutated cancers as well.
10/14/2026
Seventeen organizations secure $36 million from Google.org challenge
Unite.AI
Google.org announced that 17 organizations will receive a total of $36 million in funding through its Impact Challenge: AI for Science, which supports projects using artificial intelligence in scientific research. Among the recipients in the health and life sciences group is NYU Grossman School of Medicine. The school is receiving funding for a project that applies AI to detect diverse types of DNA damage, with the goal of uncovering unknown causes of mutations. Recipients can also join a six-month Google.org Accelerator for engineering support and technical mentorship to develop their ideas.
10/14/2026
Long past reproductive days, ovaries still busy influencing a woman's body, study finds
KFF Health News
An analysis of 6,617 pregnancies led by researchers at NYU Langone Health found a link between higher levels of the chemical DINCH in pregnant women's urine and lighter and smaller newborns. The study determined that every tenfold increase in DINCH exposure corresponded to a 27-gram reduction in newborn birth weight.
10/14/2026
Single-cell profiling exposes hidden diversity within pancreatic tumors
Inside Precision Medicine
Researchers at NYU Grossman School of Medicine discovered that genetically distinct cancer cell populations coexist within individual pancreatic tumors, which may contribute to disease progression. Published in Nature Genetics, the study used single-cell transcriptomics to identify these 'clonal ecosystems.' Lead investigator Despoina Kalfakakou, PhD, a postdoctoral research fellow at NYU Grossman School of Medicine and Perlmutter Cancer Center, noted the findings could improve biomarkers. Co-senior investigator Aristotelis Tsirigos, PhD, professor in the Departments of Medicine and Pathology at NYU Grossman School of Medicine, co-director of the Division of Precision Medicine, and director of NYU Langone’s Applied Bioinformatics Laboratories, added that this highlights an opportunity to improve treatment selection.
10/14/2026
Updated SimpleScreen CRC blood test improves precancerous lesion detection
HCP Live
An updated SimpleScreen CRC blood test showed improved sensitivity for advanced precancerous lesions at 18.2%, up from 13.7%, while maintaining 80.4% sensitivity for colorectal cancer, according to a clinical validation study. Aasma Shaukat, MD, MPH, the Robert M. and Mary H. Glickman Professor of Medicine and director of outcomes research in the Division of Gastroenterology and Hepatology at NYU Grossman School of Medicine, commented on the findings. She explained that improving advanced lesion detection is crucial for CRC prevention and that the goal of such blood tests is to provide an option for patients who decline or cannot complete colonoscopy, not to replace it or stool-based tests.
10/14/2026
The first new sunscreen type in 25 years has arrived on US store shelves
Associated Press
The US Food and Drug Administration has approved bemotrizinol, the first new sunscreen ingredient to be available in the country in over 25 years. The chemical offers broad-spectrum protection against both UVA and UVB rays and has been used for years in Europe. Jennifer A. Stein, MD, PhD, the Stewart J. Rahr Professor of Dermatology in the Ronald O. Perelman Department of Dermatology at NYU Langone Health, notes BEMT is a good option for people who dislike the feel of mineral-based sunscreens. She also explained the molecule is too large to be significantly absorbed into the bloodstream, a concern with some older chemical sunscreens.
25 years after 9/11, the mesothelioma cases are still ahead of us
Legal Reader
Twenty-five years after 9/11, deaths from related illnesses now number close to 10,000, with the caseload continuing to grow. The FDNY recently reported that 608 members have died from illnesses linked to Ground Zero. A significant concern is the anticipated increase in mesothelioma cases, which have a long latency period. In 2024, researchers at NYU Grossman School of Medicine published the first case series of mesothelioma among community members exposed to World Trade Center dust, highlighting the ongoing health crisis affecting both survivors and responders as future diagnoses are expected to rise.
10/14/2026
Scienmag
A new systematic review, co-authored by researchers from institutions including NYU Grossman School of Medicine, has analyzed 311 studies on borderline personality disorder treatment. The review found that demographic characteristics and co-morbid conditions like depression or substance use do not predict therapy outcomes, challenging common clinical assumptions. This suggests patients with these conditions should not be excluded from psychotherapy. The study did identify two promising psychological variables for predicting improvement: mindful non-judging and emotion regulation. Researchers also noted a lack of replicated findings across the literature, calling for more coordinated future studies.
10/14/2026
'Special K' didn’t retire when spravato arrived
Psychology Today
An article examines the risks of ketamine, including its use in drug-facilitated sexual assault, abuse, and addiction, referencing the death of actor Matthew Perry. It cites a survey by Joseph J. Palamar, PhD, MPH, professor in the Department of Population Health at NYU Grossman School of Medicine, which found that ketamine use among New York City nightclub attendees nearly doubled between 2017 and 2024. The author also discusses the differences between illicit use and medically supervised treatments like Spravato and calls for universities to address the issue on campuses.
10/14/2026
Education Next
The article proposes a new model for New York City's public education spending, suggesting the city's per-student allocation of roughly $42,000 be split in half. One half would go to a parent for school tuition, while the other would fund an Education Savings Account for enrichment activities like tutoring and therapy. The authors present three case studies to illustrate how families could use these funds. One case study includes a neuropsych re-evaluation at NYU Langone’s Child Study Center. The piece frames this concept as a grant proposal for a randomized controlled trial to test the model's impact.
10/14/2026
Nogapendekin alfa plus BCG has durable response in BCG-unresponsive NMIBC CIS
Renal & Urology News
Data from the QUILT-3.032 trial show that nogapendekin alfa inbakiceptpmln with Bacillus Calmette-Guérin (BCG) yields a durable response in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The median response duration was 26.6 months. In an editorial, Persily Jesse, MD, of UT Southwestern Medical Center and Katie S. Murray, DO, professor in the Department of Urology at NYU Grossman School of Medicine, wrote that the results lend credence to the idea that the treatment reignites the immune system and praised the low adverse event rate. An editorial from physicians at the Icahn School of Medicine underscored the need for comparative trials.
10/14/2026
7 doctor-approved ways to reduce (and prevent) hyperpigmentation
Everyday Health
In an article about reducing hyperpigmentation, Doris Day, MD, clinical professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, advises that a good product should include moisturizing agents like glycerin or hyaluronic acid. Dr. Day emphasizes that the most effective prevention for sun-induced discoloration is the daily application of a broad-spectrum sunscreen with an SPF of 30 or greater. She notes that prescription options can vary depending on the cause of the hyperpigmentation and may include a combination of topical treatments, such as retinol, or oral medications.
Also reporting was: Yahoo Health
10/14/2026
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
Fierce Biotech
Verastem Oncology reports promising initial data from a phase 1/2 trial for its KRAS inhibitor, VS-7375. In patients with metastatic pancreatic cancer, the drug showed a 67% progression-free survival rate and an 80% overall survival rate at six months. The confirmed overall response rate was 43% in non-small cell lung cancer patients. Commenting on the findings, Manuel Hidalgo Medina, MD, co-director of the Gastrointestinal Cancer Center at NYU Langone Health, stated that RAS inhibitors are changing the landscape for managing and treating pancreatic cancer.
Also reporting was: MarketBeat, Yahoo Finance
10/14/2026
Hilary Swank, 52, expecting her 3rd child
WTVD-TV (Durham, NC)
Following actress Hilary Swank's announcement of her third pregnancy at age 52, an article discusses the medical context of 'advanced maternal age'. Shilpi S. Mehta-Lee, MD, a maternal-fetal medicine specialist at NYU Langone, explained that while the age 35 benchmark for increased monitoring is somewhat arbitrary, pregnancy risks do increase with age, particularly after 40. She noted that women of advanced maternal age receive more frequent screening and ultrasounds, which provides an opportunity for physicians to ensure the pregnancy is progressing well.
10/14/2026
Heart doctors warn about higher-dose daily meds after president calls his 325-mg habit a 'monster'
MSN
Following President Donald Trump’s comments on his daily aspirin use, medical experts are clarifying current guidelines. Gregory Katz, MD, a clinical cardiologist at NYU Langone Health, notes that trials published around 2018 did not demonstrate a benefit for most individuals without existing heart disease. He explains that while aspirin slightly lowers the risk of heart attack and stroke, it also slightly elevates bleeding risk. The U.S. Preventive Services Task Force updated its guidance in 2022, now advising against starting aspirin for initial prevention in adults aged 60 and older. Doctors emphasize the standard preventive dose is 81 milligrams.
10/15/2026
How a controversial Hepatitis B study was funded by the CDC amid a global swirl of criticism
Rolling Stone
A controversial Hepatitis B vaccine trial in Guinea-Bissau, funded by the CDC with $1.6 million, is moving forward despite criticism. The study withholds the standard birth dose from half of the 14,000 enrolled newborns. Commenting on the accelerated ethics review, Arthur L. Caplan, founding head of the medical ethics division and professor emeritus of population health at NYU Grossman School of Medicine, stated that the process should have been slowed down, not rushed. He argued, “When subjects are in peril, in a dirt-poor nation... that is the wrong place to hurry the review.”
Also reporting was: Yahoo Entertainment, WDC News 6
10/14/2026
